{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:02:05Z","timestamp":1793037725822,"version":"4.5.0"},"reference-count":33,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>\n            <jats:bold>Background:<\/jats:bold>\n            This study estimated utility values for non-alcoholic steatohepatitis (NASH). Previous studies have assumed that health-related quality of life does not vary between the early stages of NASH.\n            <jats:bold>Materials &amp; Methods:<\/jats:bold>\n            Discrete choice experiment (DCE) surveys estimated the value of avoiding fibrosis progression. Patients also completed the EQ-5D-5L. Marginal rates of substitution estimated utility change associated with fibrosis progression.\n            <jats:bold>Results:<\/jats:bold>\n            DCE surveys were completed by the UK general public (n\u00a0=\u00a0520) and patients with NASH (n\u00a0=\u00a0154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method).\n            <jats:bold>Conclusion:<\/jats:bold>\n            Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0033","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:03:21Z","timestamp":1705417401000},"source":"Crossref","is-referenced-by-count":5,"title":["Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-0180","authenticated-orcid":false,"given":"Daniel","family":"Aggio","sequence":"first","affiliation":[{"name":"Acaster Lloyd Consulting Ltd, London,\u00a0WC1X 8NL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6826-3865","authenticated-orcid":false,"given":"Katy","family":"Gallop","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting Ltd, London,\u00a0WC1X 8NL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Villum","family":"Wittrup-Jensen","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, D-55216 Ingelheim\/Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-0428","authenticated-orcid":false,"given":"Soulmaz Fazeli","family":"Farsani","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, D-55216 Ingelheim\/Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew J","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting Ltd, London,\u00a0WC1X 8NL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6), 2005\u20132023 (2012).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi ZM","year":"2018","unstructured":"Younossi ZM, Loomba R, Anstee QM Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 68(1), 349\u2013360 (2018).","journal-title":"Hepatology"},{"issue":"4","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/hep.23478","article-title":"Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis","volume":"51","author":"Garcia-Tsao G","year":"2010","unstructured":"Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 51(4), 1445 (2010).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_9_6_2","first-page":"13","article-title":"Epidemiology and Natural History of NAFLD","volume":"34","author":"Corte CD","year":"2015","unstructured":"Corte CD, Ferrari F, Villani A, Nobili V. Epidemiology and Natural History of NAFLD. J. Med. Biochem. 34(1), 13 (2015).","journal-title":"J. Med. Biochem."},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73\u201384 (2016).","journal-title":"Hepatology"},{"issue":"5","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cgh.2020.06.064","article-title":"Real-world burden of nonalcoholic steatohepatitis","volume":"19","author":"Geier A","year":"2021","unstructured":"Geier A, Rinella ME, Balp MM Real-world burden of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 19(5), 1020\u20131029.e7 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"12","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka AC","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA 323(12), 1175\u20131183 (2020).","journal-title":"JAMA"},{"issue":"11","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes","volume":"4","author":"Younossi ZM","year":"2020","unstructured":"Younossi ZM, Wong VWS, Anstee QM Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes. Hepatol. Commun. 4(11), 1637\u20131650 (2020).","journal-title":"Hepatol. Commun."},{"key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41687-018-0052-7","article-title":"Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review","volume":"2","author":"Kennedy-Martin T","year":"2018","unstructured":"Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J. Patient Rep. Outcomes. 2, 28 (2018).","journal-title":"J. Patient Rep. Outcomes."},{"issue":"12","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Stepanova M, Anstee QM Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 17(12), 2552\u20132560.e10 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study","volume":"2","author":"O'Hara J","year":"2020","unstructured":"O'Hara J, Finnegan A, Dhillon H Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep. 2(5), 100142 (2020).","journal-title":"JHEP Rep."},{"issue":"11","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1007\/s00330-015-3731-2","article-title":"Cost-utility analysis of nonalcoholic steatohepatitis screening","volume":"25","author":"Zhang E","year":"2015","unstructured":"Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur. Radiol. 25(11), 3282\u20133294 (2015).","journal-title":"Eur. Radiol."},{"issue":"10","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman M","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20(10), 1727\u20131736 (2011).","journal-title":"Qual. Life Res."},{"issue":"1","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jhealeco.2011.11.004","article-title":"Using a discrete choice experiment to estimate health state utility values","volume":"31","author":"Bansback N","year":"2012","unstructured":"Bansback N, Brazier J, Tsuchiya A, Anis A. Using a discrete choice experiment to estimate health state utility values. J. Health Econ. 31(1), 306\u2013318 (2012).","journal-title":"J. Health Econ."},{"key":"e_1_3_9_17_2","unstructured":"VERBI Software. MAXQDA 2020. (2019)."},{"issue":"1","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Johnson FR","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 16(1), 3\u201313 (2013).","journal-title":"Value Health."},{"issue":"4","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges JFP","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 14(4), 403\u2013413 (2011).","journal-title":"Value Health."},{"key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee QM","year":"2020","unstructured":"Anstee QM, Neuschwander-Tetri BA, Wong VWS Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp. Clin. Trials. 89, 105922 (2020).","journal-title":"Contemp. Clin. Trials."},{"key":"e_1_3_9_21_2","unstructured":"OCALIVA 5 mg film-coated tablets \u2013 Summary of Product Characteristics (SmPC) - (emc). https:\/\/www.medicines.org.uk\/emc\/product\/2561\/smpc"},{"key":"e_1_3_9_22_2","unstructured":"Nonalcoholic Fatty Liver Disease & NASH. NIDDK https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash"},{"key":"e_1_3_9_23_2","unstructured":"Aggio D Gallop K Wittrup-Jensen V Farsani S Acaster S. ISPOR \u2013 A Qualitative Study of the Symptoms and Health-Related Quality of Life Impact Experienced by Patients Diagnosed with NASH (Non-Alcoholic Steatohepatitis). https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/euro2021-3408\/113771"},{"key":"e_1_3_9_24_2","unstructured":"ChoiceMetrics. Ngene 1.2 USER MANUAL & REFERENCE GUIDE The Cutting Edge in Experimental Design."},{"issue":"5","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40271-020-00485-w","article-title":"Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study","volume":"14","author":"Doward LC","year":"2021","unstructured":"Doward LC, Balp MM, Twiss J Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. Patient. 14(5), 533 (2021).","journal-title":"Patient."},{"issue":"32","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.2217\/fon-2021-0697","article-title":"Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study","volume":"17","author":"Lo SH","year":"2021","unstructured":"Lo SH, Sharma R, Costentin CE Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. Future Oncol. 17(32), 4275\u20134287 (2021).","journal-title":"Future Oncol."},{"issue":"8","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40273-021-01059-w","article-title":"Utility values associated with atypical hemolytic uremic syndrome-related attributes: a discrete choice experiment in five countries","volume":"39","author":"Williams K","year":"2021","unstructured":"Williams K, Aggio D, Chen P, Anokhina K, Lloyd AJ, Wang Y. Utility values associated with atypical hemolytic uremic syndrome-related attributes: a discrete choice experiment in five countries. Pharmacoeconomics 39(8), 901\u2013912 (2021).","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","article-title":"Conjoint analysis applications in health \u2013 how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008","volume":"3","author":"Marshall D","year":"2010","unstructured":"Marshall D, Bridges JFP, Hauber B Conjoint analysis applications in health \u2013 how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008. Patient. 3(4), 249\u2013256 (2010).","journal-title":"Patient."},{"issue":"5","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"Van Hout B","year":"2012","unstructured":"Van Hout B, Janssen MF, Feng Y Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 15(5), 708\u2013715 (2012).","journal-title":"Value Health."},{"issue":"8","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard AS","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 22(8), 931\u2013941 (2019).","journal-title":"Value Health."},{"issue":"3","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1536867X0700700306","article-title":"Fitting mixed logit models by using maximum simulated likelihood","volume":"7","author":"Hole AR","year":"2007","unstructured":"Hole AR. Fitting mixed logit models by using maximum simulated likelihood. Stata J. 7(3), 388\u2013401 (2007).","journal-title":"Stata J."},{"key":"e_1_3_9_32_2","unstructured":"National life tables UK \u2013 Office for National Statistics. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2014to2016"},{"key":"e_1_3_9_33_2","unstructured":"2011 Census data - Office for National Statistics. https:\/\/www.ons.gov.uk\/census\/2011census\/2011censusdata"},{"key":"e_1_3_9_34_2","unstructured":"Adult Health in Great Britain 2013 - Office for National Statistics. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/compendium\/opinionsandlifestylesurvey\/2015-03-19\/adulthealthingreatbritain2013"},{"issue":"6","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.22868","article-title":"Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"David K","year":"2009","unstructured":"David K, Kowdley KV, Unalp A Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49(6), 1904\u20131912 (2009).","journal-title":"Hepatology"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:39:52Z","timestamp":1706787592000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.57264\/cer-2023-0033"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0033","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"article-number":"e230033"}}